

# Review of: "[Research Note] Semaglutide, a GLP-1 Agonist Like Ozempic, and Its Potential Role as a Preventive Anti-Cancer Agent"

Haneen Yahia<sup>1</sup>

<sup>1</sup> Cairo University

Potential competing interests: No potential competing interests to declare.

Overall the study is well , but it needs english editing all over the manuscript

My specific comments are listed below

1. Authors must explain a molecular mechanism how Glp receptor activation inhibit cancer cell proliferation?
2. The authors stated that “the molecular dialogues orchestrated by Glp-1 receptor activation tilt the balance towards programmed cell death ” , if it possible to explain that molecular mechanism
3. The used dose 0.5 mg didn't show any vomiting as side effect as it well known that ozempic cause very offensive vomiting as side effect ,if not please add referenc for this point